Dr. Linda Scarazzini serves as AbbVie's Vice President of Pharmacovigilance and Patient Safety and R&D Quality Assurance. Dr. Scarazzini also serves as AbbVie’s first Chief Safety Officer. Her responsibilities include defining the safety and quality assurance strategies for AbbVie’s entire portfolio. Dr. Scarazzini has always been a leader in driving AbbVie's culture by creating and supporting multiple initiatives that focus on science, business and most importantly patients.
She has worked in the pharmaceutical industry for more than 20 years, and in 2016 was selected by her industry peers to serve as the BioPharma Representative on the FDA Drug Safety and Risk Management Advisory Committee. Before joining AbbVie, Dr. Scarazzini served as Director of the Division of Pharmacovigilance in the Office of Pharmacovigilance and Epidemiology, CDER, FDA. She began her career in pharmacovigilance at Sanofi-Aventis, ultimately serving as Associate Vice President of Pharmacovigilance and Risk Management.
Dr. Scarazzini graduated Summa Cum Laude with a pharmacy degree from Philadelphia College of Pharmacy and Science. She is board-certified in internal medicine and received her M.D. from Temple University School of Medicine and was Chief Medical Resident at The Graduate Hospital of the University of Pennsylvania.